{
  "label": "clinical_signal_03_dx_vaccine_immunogenicity_022",
  "artifact_type": "distractor_episode",
  "artifact_id": "sha256:97f9f41131ae3fdb8aa000530b4a28263f6b8ad7455e4ca444da0d5173ce5645",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:b9a5f4498416bfb2148e106e9d25ca838481bb56025a18e16baf31718f4ee4a2"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:01:12.532446",
  "content": "## 2024-07-29 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 125\n- Active: 116\n- Screen Failures Cumulative: 30\n- Withdrawals Cumulative: 9\n\n#### By Dose Group\n- Low Dose: 29\n- Mid Dose: 31\n- High Dose: 32\n- Placebo: 33\n\n### Immunogenicity By Group\n#### Low Dose\n- IgG Titer (GMU) Mean: 59.3\n- IgG Titer (GMU) SD: 6.0\n- IgM Titer (GMU) Mean: 16.1\n- IgM Titer (GMU) SD: 4.0\n- Neutralizing Ab ID50 Mean: 96.7\n- Neutralizing Ab ID50 SD: 10.0\n- CD4 Response (SFC/10^6) Mean: 146.0\n- CD4 Response (SFC/10^6) SD: 15.0\n- CD8 Response (SFC/10^6) Mean: 102.0\n- CD8 Response (SFC/10^6) SD: 11.0\n- Seroconversion Percentage: 27.5\n\n#### Mid Dose\n- IgG Titer (GMU) Mean: 97.2\n- IgG Titer (GMU) SD: 9.6\n- IgM Titer (GMU) Mean: 30.3\n- IgM Titer (GMU) SD: 6.4\n- Neutralizing Ab ID50 Mean: 153.1\n- Neutralizing Ab ID50 SD: 16.0\n- CD4 Response (SFC/10^6) Mean: 236.0\n- CD4 Response (SFC/10^6) SD: 24.0\n- CD8 Response (SFC/10^6) Mean: 166.0\n- CD8 Response (SFC/10^6) SD: 18.0\n- Seroconversion Percentage: 41.6\n\n#### High Dose\n- IgG Titer (GMU) Mean: 136.3\n- IgG Titer (GMU) SD: 13.2\n- IgM Titer (GMU) Mean: 43.9\n- IgM Titer (GMU) SD: 8.8\n- Neutralizing Ab ID50 Mean: 210.0\n- Neutralizing Ab ID50 SD: 22.0\n- CD4 Response (SFC/10^6) Mean: 308.0\n- CD4 Response (SFC/10^6) SD: 33.0\n- CD8 Response (SFC/10^6) Mean: 224.0\n- CD8 Response (SFC/10^6) SD: 24.0\n- Seroconversion Percentage: 51.7\n\n#### Placebo\n- IgG Titer (GMU) Mean: 7.0\n- IgG Titer (GMU) SD: 1.2\n- IgM Titer (GMU) Mean: 5.9\n- IgM Titer (GMU) SD: 0.8\n- Neutralizing Ab ID50 Mean: 11.2\n- Neutralizing Ab ID50 SD: 2.0\n- CD4 Response (SFC/10^6) Mean: 20.0\n- CD4 Response (SFC/10^6) SD: 3.0\n- CD8 Response (SFC/10^6) Mean: 14.0\n- CD8 Response (SFC/10^6) SD: 2.0\n- Seroconversion Percentage: 4.3\n\n### Injection Site Reactions\n- Pain Percentage: 36.1\n- Erythema Percentage: 29.8\n- Swelling Percentage: 19.6\n- Induration Percentage: 5.5\n- Mean Pain Duration (Hours): 32.5\n\n### Systemic Reactogenicity\n- Fever Percentage: 11.0\n- Fatigue Percentage: 28.3\n- Myalgia Percentage: 20.3\n- Headache Percentage: 23.2\n- Chills Percentage: 12.5\n\n### Safety Labs\n- WBC (K) Mean: 8.9\n- WBC (K) SD: 1.4\n- Lymphocyte Percentage Mean: 37.5\n- Lymphocyte Percentage SD: 5.4\n- Neutrophil Percentage Mean: 47.8\n- Neutrophil Percentage SD: 9.5\n- Platelets (K) Mean: 253\n- Platelets (K) SD: 40\n- CRP (mg/L) Mean: 7.1\n- CRP (mg/L) SD: 1.3\n- Hemoglobin (g/dL) Mean: 13.8\n- Hemoglobin (g/dL) SD: 1.1\n\n### Adverse Events\n- AE ID: VI-AE-2255, Description: myalgia, Grade: 1, Relatedness: related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-2265, Description: fever, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n\n### Events\n- Serology samples shipped to central immunology lab\n- Immunology core lab QC report received\n- Immunology core lab QC report received\n\n### Notes\n- Week 22: Immunogenicity assessments on schedule. 125 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
  "metadata": {
    "episode_type": "distractor",
    "theme": "vaccine_immunogenicity",
    "theme_index": 1,
    "local_index": 22,
    "scope_id": "clinical_signal_03",
    "layer_name": "distractor_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "86d399f4ea18a5663d6624e24cd8b639bcd4c45932ccbdc83c5254419dc5a8df",
      "components": {
        "transform": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
        "inputs": "c06ced136368edaf"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
      "components": {
        "transform_id": "01137a4997b78f86",
        "source": "c42d9c6282d5331f",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}